Organic compounds
The present invention relates to human thymic stromal lymphopoietin (hTSLP) antibodies and especially those which neutralize hTSLP activity. It further relates to methods for using anti-hTSLP antibody molecules in diagnosis or treatment of hTSLP related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease, and Hodgkin's lymphoma.
1. An isolated antibody or antigen-binding fragment thereof that specifically binds to human TSLP, wherein said antibody or said antigen-binding fragment thereof comprises: a heavy chain variable region comprising an H-CDR1 region comprising the amino acid sequence of SEQ ID NO: 3, an H-CDR2 region comprising the amino acid sequence of SEQ ID NO: 20, an H-CDR3 region comprising the amino acid sequence of SEQ ID NO: 28, and a light chain variable region comprising an L-CDR1 region comprising the amino acid sequence of SEQ ID NO: 38, an L-CDR2 region comprising the amino acid sequence of SEQ ID NO: 47, and an L-CDR3 region comprising the amino acid sequence of SEQ ID NO: 60.
2. The isolated antibody of claim 1 , which is an IgG1, IgG2 or IgG4 antibody.
3. The isolated antibody of claim 1 , which is a human antibody.
4. A composition comprising the isolated antibody or antigen-binding fragment thereof of claim 1 .